Dr. Thompson on Advancements in Treatments of Multiple Myeloma

Michael A. Thompson, MD, PhD
Published Online: Wednesday, Feb 15, 2017



Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

In the field of multiple myeloma, many drugs received FDA approval in 2016. The next important steps are to discover effective ways to use those drugs, Thompson explains. One of the most promising drugs in the field of multiple myeloma is daratumumab (Darzalex). There is now more data looking at different populations of patients treated for longer lengths of time and it still appears beneficial.

Some researchers are looking at combinations of elotuzumab (Empliciti) with checkpoint inhibitors, Thompson says. Other noteworthy drugs in this field are ixazomib (Ninlaro), selinixor, and venetoclax (Venclexta).
 


Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

In the field of multiple myeloma, many drugs received FDA approval in 2016. The next important steps are to discover effective ways to use those drugs, Thompson explains. One of the most promising drugs in the field of multiple myeloma is daratumumab (Darzalex). There is now more data looking at different populations of patients treated for longer lengths of time and it still appears beneficial.

Some researchers are looking at combinations of elotuzumab (Empliciti) with checkpoint inhibitors, Thompson says. Other noteworthy drugs in this field are ixazomib (Ninlaro), selinixor, and venetoclax (Venclexta).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Precision Medicine: The Evolving Role of Genomics and Proteomics in Cancer Treatment: Current and Emerging Roles for Molecular Testing Technologies: Real-World Application into PracticeAug 29, 20171.5
Community Practice Connections™: Oncogenic Tumor Board in NSCLC: Targeting Driver Mutations to Maximize Therapeutic OutcomesAug 31, 20171.5
Publication Bottom Border
Border Publication
$emailPop$